Skip to content

Tolerance of Healthy Term Infants Fed Infant Formulas #4

Tolerance of Healthy Term Infants Fed Infant Formulas

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01155414
Enrollment
168
Registered
2010-07-01
Start date
2010-03-31
Completion date
2010-07-31
Last updated
2011-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Term Infants

Brief summary

The primary objective of this study is to assess the comparative gastrointestinal (GI) tolerance of normal term infants to two experimental powdered formulas compared with a commercially available powdered formula.

Interventions

OTHERHydrolysate based infant formula

Infant formula ad lib

OTHERInvestigational Infant Formula A

Investigational infant formula ad lib

OTHERInvestigational Infant Formula B

Investigational infant formula ad lib

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Days to 8 Days
Healthy volunteers
Yes

Inclusion criteria

* Singleton full term birth in good health * Birth weight was \> 2490 g. * Between 0 and 8 days of age. * Infants using medications (including OTC such as Mylicon® for gas), home remedies (such as juice for constipation), herbal preparations or rehydration fluids that might affect GI tolerance may not be enrolled unless both the parent and the physician agree to discontinue these agents prior to enrollment. * Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study, unless instructed otherwise by their healthcare professional. * Parent(s) confirm their intention not to administer vitamin or mineral supplements, solid foods or juices to their infant from enrollment through the duration of the study.

Exclusion criteria

• An adverse maternal, fetal or infant medical history and treatment with antibiotics

Design outcomes

Primary

MeasureTime frame
GI tolerance via stool consistency28 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026